Last reviewed · How we verify
Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy
Approved treatments
- Palbociclib in combination with AI · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy patent landscape — cliff calendar, originator estates, attackable patents
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy treatment landscape brief
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy treatment updates RSS
Frequently asked questions about Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy
What drugs treat Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy?
Tracked treatments include Palbociclib in combination with AI.
What is the treatment for Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy?
Standard treatment for Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy includes Palbociclib in combination with AI. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy patent cliff · Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy CI report
- Treatment: Palbociclib in combination with AI · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing